In brief

BMJ 2005; 331 doi: (Published 22 September 2005) Cite this as: BMJ 2005;331:652

CJD study gets the go ahead: A study by the Medical Research Council to monitor pentosan polysulphate as a treatment for Creutzfeldt-Jakob disease (CJD) and variant CJD has received ethical approval from an NHS monitoring body. It follows two High Court cases in the UK, in which relatives sought use of this experimental treatment that has showed signs …

View Full Text

Log in

Log in through your institution


* For online subscription